Nonaka Michiko, Sato Seiya, Osaku Daiken, Sawada Mayumi, Kudoh Akiko, Chikumi Jun, Sato Shinya, Oishi Tetsuro, Harada Tasuku
Department of Obstetrics and Gynecology, Tottori University School of Medicine, 36-1 Nishicho, Yonago-City, Tottori 683-8504, Japan.
Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka-City, Iwate 020-8505, Japan.
Gynecol Oncol Rep. 2018 Aug 24;26:21-23. doi: 10.1016/j.gore.2018.08.005. eCollection 2018 Nov.
Bevacizumab (Bev) is an antiangiogenic drug used to treat various malignances, including ovarian cancer (OC). Bev is generally well-tolerated; however, it has a characteristic toxicity profile. In particular, gastrointestinal perforation (GIP) is a rare but serious side effect that can be lethal. A 55-year-old woman with recurrent OC had an episode of GIP during third-line chemotherapy comprising Bev and topotecan (TPT). Bev was discontinued while TPT was continued as monotherapy. Three months after discontinuation of Bev, the patient presented with left lower abdominal pain and was diagnosed with a second GIP. She had emergent surgery. One year later, she is still alive and healthy, and is continuing TPT. This is the first report of recurrent GIP after discontinuation of Bev. Our case suggests that physicians should be aware of GIP even after the discontinuation of Bev.
贝伐单抗（Bev）是一种用于治疗包括卵巢癌（OC）在内的多种恶性肿瘤的抗血管生成药物。Bev通常耐受性良好；然而，它具有独特的毒性特征。特别是，胃肠道穿孔（GIP）是一种罕见但严重的副作用，可能致命。一名55岁复发性OC女性在接受包含Bev和拓扑替康（TPT）的三线化疗期间发生了一次GIP。停用Bev，而TPT继续作为单一疗法使用。停用Bev三个月后，患者出现左下腹疼痛，被诊断为第二次GIP。她接受了急诊手术。一年后，她仍然健在且健康，并继续接受TPT治疗。这是停用Bev后复发性GIP的首例报告。我们的病例表明，即使在停用Bev后，医生也应意识到GIP的存在。
